Free Trial
→ M.A.G.A. is Finished – This Could be even Better (From Paradigm Press) (Ad) Buy ZBH Stock  Free ZBH Stock Alerts

Zimmer Biomet (ZBH) Financials

Zimmer Biomet logo
$101.84 -0.51 (-0.50%)
As of 03:58 PM Eastern
Compare
Annual Income Statements for Zimmer Biomet

Annual Income Statements for Zimmer Biomet

This table shows Zimmer Biomet's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 147 306 1,814 -379 1,132 -139 401 230 1,023 902
Consolidated Net Income / (Loss)		 146 305 1,813 -379 1,132 -137 402 231 1,024 904
Net Income / (Loss) Continuing Operations		 146 305 1,813 -379 1,132 -9.20 891 291 1,025 905
Total Pre-Tax Income 		153 400 465 -271 906 -105 499 404 1,067 1,037
Total Operating Income		 467 821 799 34 1,138 83 860 696 1,278 1,286
Total Gross Profit		 4,197 5,233 5,670 5,661 5,730 4,303 4,867 4,920 5,310 5,487
Total Revenue		 5,998 7,615 7,803 7,933 7,982 6,128 6,827 6,940 7,394 7,679
Operating Revenue		 5,998 7,615 7,803 7,933 7,982 6,128 6,827 6,940 7,394 7,679
Total Cost of Revenue		 1,801 2,382 2,133 2,272 2,253 1,824 1,960 2,020 2,084 2,191
Operating Cost of Revenue		 1,801 2,382 2,133 2,272 2,253 1,824 1,960 2,020 2,084 2,191
Total Operating Expenses		 3,730 4,412 4,871 5,627 4,592 4,220 4,007 4,224 4,033 4,202
Selling, General & Admin Expense		 2,284 2,945 3,105 3,379 3,344 2,713 2,843 2,762 2,839 2,930
Research & Development Expense		 269 366 370 392 449 323 436 406 459 437
Amortization Expense		 337 566 604 596 584 512 530 527 562 592
Other Operating Expenses / (Income)		 - - 444 246 95 51 56 34 22 24
Impairment Charge		 0.00 31 332 980 70 503 16 293 0.00 0.00
Restructuring Charge		 - 505 18 34 50 119 126 203 152 219
Total Other Income / (Expense), net		 -314 -422 -335 -305 -232 -188 -361 -293 -211 -249
Interest Expense		 287 355 325 289 227 212 374 165 201 218
Other Income / (Expense), net		 -37 -67 -9.40 -16 -4.80 24 12 -128 -9.30 -31
Income Tax Expense		 7.00 95 -1,349 108 -226 -96 54 112 42 131
Net Income / (Loss) Discontinued Operations		 - - - - - -128 -43 -59 0.00 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.80 -1.30 -0.40 -0.10 -0.10 1.50 0.50 1.00 1.10 1.50
Basic Earnings per Share		 $0.78 $1.53 $8.98 ($1.86) $5.52 ($0.67) $1.93 $1.10 $4.91 $4.45
Weighted Average Basic Shares Outstanding		 187.40M 200M 201.90M 203.50M 205.10M 207M 208.60M 209.60M 208.70M 203.10M
Diluted Earnings per Share		 $0.77 $1.51 $8.90 ($1.86) $5.47 ($0.67) $1.91 $1.10 $4.88 $4.43
Weighted Average Diluted Shares Outstanding		 189.80M 202.40M 203.70M 203.50M 206.70M 207M 210.40M 210.30M 209.70M 203.90M
Weighted Average Basic & Diluted Shares Outstanding		 188.50M 199.90M 202M 203.90M 206.40M 207.86M 209.18M 208.98M 205.08M 199.06M
Cash Dividends to Common per Share		 $0.88 $0.96 $0.96 $0.96 $0.96 $0.96 $0.96 $0.96 $0.96 $0.96

Quarterly Income Statements for Zimmer Biomet

This table shows Zimmer Biomet's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 194 -131 233 209 163 419 172 243 249 239
Consolidated Net Income / (Loss)		 194 -131 233 210 163 419 173 243 249 239
Net Income / (Loss) Continuing Operations		 194 -284 233 210 163 420 173 243 249 240
Total Pre-Tax Income 		178 -75 287 277 219 285 215 302 230 289
Total Operating Income		 245 -28 327 330 267 354 266 351 280 389
Total Gross Profit		 1,182 1,305 1,330 1,344 1,235 1,401 1,377 1,388 1,286 1,437
Total Revenue		 1,670 1,825 1,831 1,870 1,754 1,940 1,889 1,942 1,824 2,023
Operating Revenue		 1,670 1,825 1,831 1,870 1,754 1,940 1,889 1,942 1,824 2,023
Total Cost of Revenue		 488 520 501 526 519 539 512 554 539 587
Operating Cost of Revenue		 488 520 501 526 519 539 512 554 539 587
Total Operating Expenses		 936 1,333 1,003 1,014 968 1,047 1,111 1,037 1,006 1,047
Selling, General & Admin Expense		 655 727 716 726 675 722 736 737 710 747
Research & Development Expense		 102 108 110 118 117 113 108 109 112 109
Amortization Expense		 132 132 133 138 145 145 142 144 148 158
Other Operating Expenses / (Income)		 20 2.90 1.30 7.90 7.30 5.20 0.40 5.20 4.40 14
Restructuring Charge		 28 74 42 24 24 61 124 42 32 21
Total Other Income / (Expense), net		 -68 -47 -41 -53 -47 -70 -51 -49 -49 -100
Interest Expense		 42 43 48 52 51 50 51 51 54 62
Other Income / (Expense), net		 -25 -3.90 7.70 -1.20 3.80 -20 -0.10 2.00 5.10 -38
Income Tax Expense		 -17 55 54 67 56 -135 42 59 -19 49
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.20 0.30 0.20 0.20 0.20 0.50 0.40 0.30 0.20 0.60
Basic Earnings per Share		 $0.92 ($0.62) $1.11 $1.00 $0.78 $2.02 $0.84 $1.18 $1.23 $1.20
Weighted Average Basic Shares Outstanding		 209.80M 209.60M 209.40M 208.60M 208.90M 208.70M 205.20M 205.70M 202.30M 203.10M
Diluted Earnings per Share		 $0.92 ($0.62) $1.11 $1.00 $0.77 $2.00 $0.84 $1.18 $1.23 $1.18
Weighted Average Diluted Shares Outstanding		 210.30M 210.30M 210.40M 209.90M 210M 209.70M 206.20M 206.40M 203M 203.90M
Weighted Average Basic & Diluted Shares Outstanding		 209.85M 208.98M 208.57M 208.96M 208.98M 205.08M 205.73M 203.65M 199.07M 199.06M
Cash Dividends to Common per Share		 $0.24 $0.24 $0.24 $0.24 $0.24 $0.24 $0.24 $0.24 $0.24 $0.24

Annual Cash Flow Statements for Zimmer Biomet

This table details how cash moves in and out of Zimmer Biomet's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 376 -825 -110 29 75 169 -324 -103 40 110
Net Cash From Operating Activities		 850 1,632 1,582 1,747 1,586 1,076 1,404 1,356 1,582 1,499
Net Cash From Continuing Operating Activities		 850 1,632 1,582 1,747 1,586 1,076 1,404 1,356 1,582 1,499
Net Income / (Loss) Continuing Operations		 146 305 1,813 -379 1,132 -9.20 446 291 1,025 905
Depreciation Expense		 712 1,039 1,063 1,041 1,006 898 938 926 952 996
Non-Cash Adjustments To Reconcile Net Income		 446 465 418 1,045 154 577 257 514 97 101
Changes in Operating Assets and Liabilities, net		 -455 -177 -1,712 41 -706 -390 -236 -376 -493 -503
Net Cash From Discontinued Operating Activities		 - - - - - - - - 0.00 0.00
Net Cash From Investing Activities		 -7,558 -1,692 -511 -417 -729 -564 -443 -522 -779 -888
Net Cash From Continuing Investing Activities		 -7,558 -1,692 -511 -417 -729 -564 -443 -522 -779 -888
Purchase of Property, Plant & Equipment		 -168 -185 -156 -163 -207 -112 -144 -188 -291 -204
Acquisitions		 -7,760 -1,443 -4.00 -15 -235 -227 -8.40 -130 -238 -429
Purchase of Investments		 -215 -1.50 - - 48 54 - 89 33 22
Other Investing Activities, net		 -288 -349 -351 -308 -336 -279 -293 -294 -283 -277
Net Cash From Discontinued Investing Activities		 - - - - - - - - 0.00 0.00
Net Cash From Financing Activities		 7,107 -743 -1,211 -1,302 -780 -420 -1,306 -776 -764 -485
Net Cash From Continuing Financing Activities		 7,107 -743 -1,211 -1,302 -780 -420 -1,306 -776 -764 -485
Repayment of Debt		 -3,320 -2,099 -1,850 -2,984 -1,476 -1,781 -2,674 -1,525 -136 -885
Repurchase of Common Equity		 -150 -416 - - - 0.00 0.00 -126 -692 -868
Payment of Dividends		 -157 -188 -194 -195 -197 -199 -345 -201 -201 -196
Issuance of Debt		 10,628 1,824 593 1,825 749 1,497 1,600 458 175 1,386
Issuance of Common Equity		 105 137 146 108 158 130 123 78 101 82
Other Financing Activities, net		 0.70 0.00 94 -57 -15 -68 -8.90 541 -10 -3.50
Net Cash From Discontinued Financing Activities		 - - - - - - - - 0.00 0.00
Other Net Changes in Cash		 - -23 29 - -1.50 78 21 -161 0.90 -17

Quarterly Cash Flow Statements for Zimmer Biomet

This table details how cash moves in and out of Zimmer Biomet's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 159 -170 -46 -10 -28 124 -23 27 149 -44
Net Cash From Operating Activities		 451 244 308 348 338 588 228 369 396 506
Net Cash From Continuing Operating Activities		 451 244 308 348 338 589 228 369 396 506
Net Income / (Loss) Continuing Operations		 194 -130 233 210 163 420 173 243 249 240
Depreciation Expense		 231 229 232 238 241 241 239 243 251 264
Non-Cash Adjustments To Reconcile Net Income		 57 319 25 34 16 23 29 26 25 21
Changes in Operating Assets and Liabilities, net		 -32 -173 -182 -133 -82 -95 -212 -143 -129 -19
Net Cash From Investing Activities		 -85 -113 -149 -243 -166 -221 -195 -247 -155 -291
Net Cash From Continuing Investing Activities		 -85 -113 -149 -243 -166 -221 -195 -247 -155 -291
Purchase of Property, Plant & Equipment		 -47 -63 -47 -97 -84 -63 -55 -53 -45 -52
Acquisitions		 - -30 -33 - -98 -107 -13 -54 -169 -193
Purchase of Investments		 37 18 - - 8.20 6.20 - - 2.80 2.80
Other Investing Activities, net		 -75 -38 -83 -152 8.80 -57 -138 -147 56 -49
Net Cash From Financing Activities		 -194 -313 -207 -109 -196 -251 -50 -92 -102 -241
Net Cash From Continuing Financing Activities		 -194 -313 -207 -109 -196 -251 -50 -92 -102 -241
Repayment of Debt		 -25 -527 -125 -0.10 -22 11 -11 -2.00 -57 -816
Repurchase of Common Equity		 - -126 -268 -14 - -410 -114 -86 -596 -72
Payment of Dividends		 -50 -50 -50 -54 -50 -46 -51 -56 -50 -39
Issuance of Debt		 -137 375 210 -65 -145 175 70 45 585 686
Issuance of Common Equity		 18 15 36 25 21 19 56 6.60 19 0.50

Annual Balance Sheets for Zimmer Biomet

This table presents Zimmer Biomet's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets		 27,161 26,684 26,014 24,127 24,639 24,418 23,456 21,066 21,497 21,365
Total Current Assets		 5,854 4,664 4,565 4,427 4,724 5,083 4,885 4,427 4,610 4,672
Cash & Equivalents		 1,459 634 524 543 618 802 378 376 416 526
Accounts Receivable		 1,447 1,604 1,544 1,276 1,364 1,453 1,260 1,382 1,442 1,481
Inventories, net		 2,254 1,959 2,068 2,257 2,385 2,451 2,148 2,147 2,385 2,235
Prepaid Expenses		 529 466 428 352 357 169 271 523 366 430
Current Deferred & Refundable Income Taxes		 - - - - - 209 327 0.00 0.00 0.00
Other Current Nonoperating Assets		 - - - - - - 502 0.00 0.00 0.00
Plant, Property, & Equipment, net		 2,063 2,038 2,039 2,015 2,077 2,048 1,837 1,873 2,060 2,049
Total Noncurrent Assets		 19,244 19,983 19,411 17,684 17,837 17,287 16,735 14,766 14,827 14,645
Goodwill		 9,934 10,644 10,668 9,594 9,600 9,262 8,919 8,580 8,819 8,951
Intangible Assets		 8,746 8,785 8,353 7,685 7,258 7,056 5,534 5,064 4,856 4,598
Other Noncurrent Operating Assets		 564 554 389 405 980 969 1,005 1,122 1,152 1,096
Other Noncurrent Nonoperating Assets		 - - - - - - 1,277 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 27,161 26,684 26,014 24,127 24,639 24,418 23,456 21,066 21,497 21,365
Total Liabilities		 17,271 17,015 14,279 12,851 12,246 12,218 10,790 9,039 9,009 8,889
Total Current Liabilities		 1,618 2,382 3,070 2,421 3,442 2,557 3,468 2,358 2,857 2,451
Short-Term Debt		 0.00 576 1,225 525 1,500 500 1,605 544 900 863
Accounts Payable		 285 365 330 363 401 330 307 354 411 195
Other Current Liabilities		 1,186 1,258 1,349 1,391 1,414 1,667 1,317 1,421 1,547 1,393
Other Current Nonoperating Liabilities		 - - - - - - 177 0.00 0.00 0.00
Total Noncurrent Liabilities		 15,653 14,633 11,209 10,429 8,804 9,661 7,322 6,681 6,151 6,438
Long-Term Debt		 11,497 10,666 8,918 8,414 6,721 7,627 5,464 5,152 4,868 5,342
Noncurrent Deferred & Payable Income Tax Liabilities		 3,150 3,031 1,102 1,000 840 790 559 475 358 353
Other Noncurrent Operating Liabilities		 1,006 463 446 350 558 656 549 633 926 744
Other Noncurrent Nonoperating Liabilities		 - - - - - - 168 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 9,889 9,670 11,736 11,276 12,393 12,199 12,666 12,027 12,488 12,476
Total Preferred & Common Equity		 9,888 9,669 11,736 11,271 12,388 12,194 12,661 12,020 12,481 12,468
Total Common Equity		 9,888 9,669 11,736 11,271 12,388 12,194 12,661 12,020 12,481 12,468
Common Stock		 8,198 8,372 8,518 8,689 8,923 9,125 9,318 9,508 9,849 10,041
Retained Earnings		 8,348 8,467 10,023 9,491 10,427 10,087 10,292 9,559 10,385 11,095
Treasury Stock		 -6,329 -6,736 -6,722 -6,722 -6,721 -6,720 -6,718 -6,867 -7,562 -8,406
Accumulated Other Comprehensive Income / (Loss)		 -329 -434 -83 -187 -242 -298 -232 -179 -191 -263
Noncontrolling Interest		 1.50 1.00 -0.30 4.80 4.70 5.20 5.70 6.70 7.70 8.10

Quarterly Balance Sheets for Zimmer Biomet

This table presents Zimmer Biomet's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Total Assets		 21,333 21,066 21,244 21,294 21,217 21,497 21,452 21,520 21,720 21,365
Total Current Assets		 4,534 4,427 4,412 4,388 4,372 4,610 4,632 4,639 4,864 4,672
Cash & Equivalents		 545 376 330 320 292 416 393 420 569 526
Accounts Receivable		 1,279 1,382 1,381 1,367 1,341 1,442 1,446 1,418 1,482 1,481
Inventories, net		 2,129 2,147 2,241 2,276 2,323 2,385 2,388 2,370 2,369 2,235
Prepaid Expenses		 347 523 460 425 416 366 404 431 445 430
Current Deferred & Refundable Income Taxes		 235 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Current Nonoperating Assets		 0.00 0.00 0.00 - - 0.00 - - - 0.00
Plant, Property, & Equipment, net		 1,802 1,873 1,906 1,975 2,032 2,060 2,091 2,103 2,107 2,049
Total Noncurrent Assets		 14,997 14,766 14,925 14,931 14,813 14,827 14,730 14,778 14,749 14,645
Goodwill		 8,799 8,580 8,735 8,744 8,710 8,819 8,792 8,825 8,912 8,951
Intangible Assets		 5,137 5,064 5,072 5,028 4,892 4,856 4,734 4,707 4,665 4,598
Other Noncurrent Operating Assets		 1,062 1,122 1,119 1,160 1,211 1,152 1,204 1,246 1,172 1,096
Other Noncurrent Nonoperating Assets		 0.00 0.00 0.00 - - 0.00 - - - 0.00
Total Liabilities & Shareholders' Equity		 21,333 21,066 21,244 21,294 21,217 21,497 21,452 21,520 21,720 21,365
Total Liabilities		 9,082 9,039 9,086 8,916 8,699 9,009 8,846 8,771 9,337 8,889
Total Current Liabilities		 2,296 2,358 2,336 2,234 2,072 2,857 2,797 3,608 3,571 2,451
Short-Term Debt		 659 544 585 520 355 900 970 1,878 1,713 863
Accounts Payable		 334 354 397 355 320 411 370 342 322 195
Other Current Liabilities		 1,156 1,421 1,073 1,278 1,300 1,547 1,386 1,389 1,536 1,393
Other Current Nonoperating Liabilities		 0.00 0.00 0.00 - - 0.00 - - - 0.00
Total Noncurrent Liabilities		 6,787 6,681 6,750 6,682 6,628 6,151 6,049 5,162 5,766 6,438
Long-Term Debt		 5,055 5,152 5,205 5,189 5,127 4,868 4,826 3,957 4,738 5,342
Noncurrent Deferred & Payable Income Tax Liabilities		 541 475 485 475 465 358 370 0.00 0.00 353
Other Noncurrent Operating Liabilities		 609 633 637 642 632 926 577 1,205 1,028 744
Other Noncurrent Nonoperating Liabilities		 0.00 0.00 0.00 - - 0.00 - - - 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 12,251 12,027 12,158 12,379 12,518 12,488 12,606 12,749 12,383 12,476
Total Preferred & Common Equity		 12,245 12,020 12,151 12,372 12,511 12,481 12,598 12,741 12,375 12,468
Total Common Equity		 12,245 12,020 12,151 12,372 12,511 12,481 12,598 12,741 12,375 12,468
Common Stock		 9,467 9,508 9,696 9,769 9,805 9,849 9,949 9,978 10,021 10,041
Retained Earnings		 9,740 9,559 9,742 9,902 10,015 10,385 10,509 10,703 10,904 11,095
Treasury Stock		 -6,717 -6,867 -7,109 -7,122 -7,122 -7,562 -7,649 -7,744 -8,348 -8,406
Accumulated Other Comprehensive Income / (Loss)		 -245 -179 -178 -178 -187 -191 -211 -195 -202 -263
Noncontrolling Interest		 6.40 6.70 6.90 7.10 7.20 7.70 8.10 8.40 8.50 8.10

Annual Metrics and Ratios for Zimmer Biomet

This table displays calculated financial ratios and metrics derived from Zimmer Biomet's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 28.34% 26.96% 2.47% 1.66% 0.62% -23.24% 11.42% 1.65% 6.55% 3.85%
EBITDA Growth		 -16.36% 56.97% 3.27% -42.85% 102.02% -53.00% 80.07% -17.43% 48.53% 1.39%
EBIT Growth		 -56.55% 75.33% 4.68% -97.70% 6,123.63% -90.56% 716.18% -34.87% 123.19% -1.09%
NOPAT Growth		 -43.85% 40.35% 398.45% -99.24% 5,905.63% -95.91% 1,220.38% -34.57% 144.21% -8.51%
Net Income Growth		 -79.67% 108.34% 495.34% -120.92% 398.31% -112.14% 392.29% -42.38% 342.52% -11.74%
EPS Growth		 -81.67% 96.10% 489.40% -120.90% 394.09% -112.25% 385.07% -42.41% 343.64% -9.22%
Operating Cash Flow Growth		 -19.87% 92.07% -3.06% 10.43% -9.25% -32.17% 30.56% -3.43% 16.62% -5.20%
Free Cash Flow Firm Growth		 -2,023.92% 100.86% 1,731.09% -16.55% -35.69% -51.61% 346.15% -54.43% -31.90% 9.90%
Invested Capital Growth		 214.63% 2.60% 5.31% -7.88% 1.65% -2.36% -8.19% -3.22% 2.84% 1.77%
Revenue Q/Q Growth		 13.44% 0.14% 3.79% -1.96% 0.69% -13.27% 9.44% 0.70% 1.58% 1.10%
EBITDA Q/Q Growth		 22.92% -6.89% -7.64% -41.86% 113.73% -4.41% -9.31% -10.04% 20.62% 1.75%
EBIT Q/Q Growth		 5.23% -11.75% -17.34% -97.64% 18,079.37% 250.49% -24.82% -22.20% 40.68% 1.32%
NOPAT Q/Q Growth		 15.46% 1.50% 191.31% -99.19% 19,801.02% 901.20% -33.53% -37.04% 104.24% -14.61%
Net Income Q/Q Growth		 -13.29% -15.76% 178.17% -121.62% 1,324.57% 8.28% -50.99% -16.79% 115.85% -16.59%
EPS Q/Q Growth		 -20.62% -17.49% 178.13% -121.65% 1,263.83% 0.00% 0.00% -17.29% 115.93% -15.62%
Operating Cash Flow Q/Q Growth		 7.99% 11.22% -12.42% -1.32% 2.84% -10.57% 3.04% -6.44% 27.82% -5.19%
Free Cash Flow Firm Q/Q Growth		 1.55% 189.18% 34.76% -29.59% 11.44% -26.66% 123.73% -59.69% 134.94% 6.54%
Invested Capital Q/Q Growth		 -1.67% -2.70% 4.70% -5.86% 0.39% 1.68% -7.12% -0.41% 0.75% -0.60%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 69.98% 68.72% 72.67% 71.36% 71.78% 70.23% 71.29% 70.90% 71.82% 71.46%
EBITDA Margin		 19.05% 23.56% 23.74% 13.35% 26.79% 16.41% 26.51% 21.54% 30.02% 29.31%
Operating Margin		 7.79% 10.78% 10.24% 0.43% 14.25% 1.36% 12.60% 10.03% 17.28% 16.74%
EBIT Margin		 7.18% 9.91% 10.12% 0.23% 14.19% 1.74% 12.78% 8.19% 17.15% 16.34%
Profit (Net Income) Margin		 2.44% 4.00% 23.24% -4.78% 14.18% -2.24% 5.88% 3.33% 13.85% 11.77%
Tax Burden Percent		 95.43% 76.23% 390.31% 139.91% 124.92% 130.61% 80.48% 57.35% 95.94% 87.19%
Interest Burden Percent		 35.59% 52.96% 58.82% -1,489.56% 79.97% -98.41% 57.19% 71.00% 84.15% 82.62%
Effective Tax Rate		 4.57% 23.77% -290.31% 0.00% -24.92% 0.00% 10.72% 27.83% 3.95% 12.68%
Return on Invested Capital (ROIC)		 3.42% 3.13% 14.99% 0.12% 7.16% 0.29% 4.10% 2.85% 6.98% 6.24%
ROIC Less NNEP Spread (ROIC-NNEP)		 -2.82% -0.01% 2.07% -4.36% 3.55% -2.33% -1.72% -2.28% 3.17% 2.27%
Return on Net Nonoperating Assets (RNNOA)		 -1.65% -0.01% 1.96% -3.41% 2.40% -1.41% -0.87% -0.98% 1.38% 1.00%
Return on Equity (ROE)		 1.78% 3.11% 16.94% -3.30% 9.56% -1.12% 3.23% 1.87% 8.35% 7.24%
Cash Return on Invested Capital (CROIC)		 -100.10% 0.56% 9.82% 8.31% 5.53% 2.69% 12.64% 6.12% 4.18% 4.49%
Operating Return on Assets (OROA)		 2.34% 2.80% 3.00% 0.07% 4.65% 0.44% 3.65% 2.55% 5.96% 5.85%
Return on Assets (ROA)		 0.79% 1.13% 6.88% -1.51% 4.64% -0.56% 1.68% 1.04% 4.81% 4.22%
Return on Common Equity (ROCE)		 1.78% 3.11% 16.94% -3.30% 9.56% -1.12% 3.23% 1.87% 8.35% 7.24%
Return on Equity Simple (ROE_SIMPLE)		 1.48% 3.15% 15.45% -3.37% 9.13% -1.13% 3.17% 1.93% 8.20% 7.25%
Net Operating Profit after Tax (NOPAT)		 446 626 3,120 24 1,421 58 768 503 1,227 1,123
NOPAT Margin		 7.44% 8.22% 39.98% 0.30% 17.80% 0.95% 11.25% 7.24% 16.60% 14.62%
Net Nonoperating Expense Percent (NNEP)		 6.24% 3.14% 12.92% 4.47% 3.62% 2.62% 5.83% 5.13% 3.81% 3.97%
Return On Investment Capital (ROIC_SIMPLE)		 2.09% 2.99% 14.26% 0.12% 6.89% 0.29% 3.89% 2.84% 6.72% 6.01%
Cost of Revenue to Revenue		 30.02% 31.28% 27.33% 28.64% 28.22% 29.77% 28.71% 29.10% 28.18% 28.54%
SG&A Expenses to Revenue		 38.08% 38.67% 39.79% 42.60% 41.89% 44.27% 41.65% 39.79% 38.39% 38.16%
R&D to Revenue		 4.48% 4.80% 4.74% 4.94% 5.63% 5.27% 6.38% 5.85% 6.20% 5.70%
Operating Expenses to Revenue		 62.19% 57.94% 62.42% 70.94% 57.53% 68.87% 58.69% 60.87% 54.54% 54.72%
Earnings before Interest and Taxes (EBIT)		 430 755 790 18 1,133 107 873 568 1,268 1,255
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 1,143 1,794 1,853 1,059 2,139 1,005 1,810 1,495 2,220 2,251
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.92 1.96 1.92 1.75 2.33 2.48 1.99 2.19 2.02 1.69
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 3.16 2.49 2.89 2.48 3.62 4.93 3.70 3.79 3.41 2.74
Price to Earnings (P/E)		 129.12 61.88 12.43 0.00 25.52 0.00 62.96 114.25 24.65 23.31
Dividend Yield		 0.94% 1.02% 0.86% 0.99% 0.68% 0.66% 0.79% 0.77% 0.80% 0.91%
Earnings Yield		 0.77% 1.62% 8.04% 0.00% 3.92% 0.00% 1.59% 0.88% 4.06% 4.29%
Enterprise Value to Invested Capital (EV/IC)		 1.46 1.46 1.51 1.43 1.82 1.92 1.78 1.82 1.71 1.47
Enterprise Value to Revenue (EV/Rev)		 4.81 3.88 4.12 3.54 4.57 6.12 4.68 4.56 4.14 3.48
Enterprise Value to EBITDA (EV/EBITDA)		 25.25 16.47 17.37 26.54 17.06 37.33 17.65 21.18 13.77 11.87
Enterprise Value to EBIT (EV/EBIT)		 67.04 39.14 40.73 1,543.84 32.21 351.02 36.62 55.69 24.11 21.29
Enterprise Value to NOPAT (EV/NOPAT)		 64.71 47.19 10.31 1,187.57 25.68 645.08 41.60 62.99 24.92 23.80
Enterprise Value to Operating Cash Flow (EV/OCF)		 33.96 18.10 20.33 16.08 23.01 34.89 22.75 23.34 19.33 17.82
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 264.69 15.74 16.48 33.27 70.71 13.49 29.33 41.61 33.08
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 1.16 1.16 0.86 0.79 0.66 0.67 0.56 0.47 0.46 0.50
Long-Term Debt to Equity		 1.16 1.10 0.76 0.75 0.54 0.63 0.43 0.43 0.39 0.43
Financial Leverage		 0.58 1.05 0.94 0.78 0.68 0.61 0.51 0.43 0.44 0.44
Leverage Ratio		 2.24 2.75 2.46 2.18 2.06 1.99 1.93 1.80 1.74 1.72
Compound Leverage Factor		 0.80 1.46 1.45 -32.46 1.65 -1.96 1.10 1.28 1.46 1.42
Debt to Total Capital		 53.76% 53.76% 46.36% 44.22% 39.88% 39.98% 35.82% 32.14% 31.59% 33.21%
Short-Term Debt to Total Capital		 0.00% 2.75% 5.60% 2.60% 7.28% 2.46% 8.13% 3.07% 4.93% 4.62%
Long-Term Debt to Total Capital		 53.76% 51.01% 40.76% 41.62% 32.61% 37.52% 27.69% 29.07% 26.66% 28.59%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.01% 0.00% 0.00% 0.02% 0.02% 0.03% 0.03% 0.04% 0.04% 0.04%
Common Equity to Total Capital		 46.23% 46.24% 53.64% 55.76% 60.10% 59.99% 64.15% 67.82% 68.36% 66.74%
Debt to EBITDA		 10.06 6.27 5.47 8.44 3.84 8.08 3.91 3.81 2.60 2.76
Net Debt to EBITDA		 8.64 5.91 5.19 7.93 3.56 7.29 3.70 3.56 2.41 2.52
Long-Term Debt to EBITDA		 10.06 5.95 4.81 7.95 3.14 7.59 3.02 3.45 2.19 2.37
Debt to NOPAT		 25.78 17.96 3.25 377.80 5.79 139.70 9.20 11.34 4.70 5.53
Net Debt to NOPAT		 22.14 16.95 3.08 354.86 5.35 125.91 8.71 10.59 4.36 5.06
Long-Term Debt to NOPAT		 25.78 17.04 2.86 355.61 4.73 131.11 7.11 10.25 3.97 4.76
Altman Z-Score		 1.55 1.59 1.96 1.90 2.55 2.45 2.50 2.92 2.99 2.82
Noncontrolling Interest Sharing Ratio		 0.02% 0.01% 0.00% 0.02% 0.04% 0.04% 0.04% 0.05% 0.06% 0.06%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 3.62 1.96 1.49 1.83 1.37 1.99 1.41 1.88 1.61 1.91
Quick Ratio		 1.90 0.94 0.67 0.75 0.58 0.88 0.47 0.75 0.65 0.82
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -13,036 112 2,043 1,705 1,097 531 2,368 1,079 735 808
Operating Cash Flow to CapEx		 868.92% 883.70% 1,014.29% 1,074.00% 765.72% 961.22% 977.92% 721.77% 543.32% 735.72%
Free Cash Flow to Firm to Interest Expense		 -45.48 0.31 6.28 5.89 4.83 2.50 6.34 6.55 3.65 3.70
Operating Cash Flow to Interest Expense		 2.97 4.60 4.86 6.04 6.99 5.07 3.76 8.23 7.86 6.88
Operating Cash Flow Less CapEx to Interest Expense		 2.62 4.08 4.38 5.48 6.08 4.54 3.38 7.09 6.41 5.94
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.33 0.28 0.30 0.32 0.33 0.25 0.29 0.31 0.35 0.36
Accounts Receivable Turnover		 5.09 4.99 4.96 5.63 6.05 4.35 5.03 5.26 5.24 5.25
Inventory Turnover		 1.04 1.13 1.06 1.05 0.97 0.75 0.85 0.94 0.92 0.95
Fixed Asset Turnover		 3.58 3.71 3.83 3.91 3.90 2.97 3.52 3.74 3.76 3.74
Accounts Payable Turnover		 8.37 7.34 6.14 6.56 5.90 4.99 6.16 6.11 5.45 7.24
Days Sales Outstanding (DSO)		 71.77 73.12 73.64 64.87 60.35 83.89 72.50 69.45 69.70 69.47
Days Inventory Outstanding (DIO)		 349.41 322.85 344.63 347.41 376.04 483.76 428.11 388.15 396.95 384.83
Days Payable Outstanding (DPO)		 43.58 49.75 59.44 55.65 61.86 73.12 59.25 59.70 66.97 50.41
Cash Conversion Cycle (CCC)		 377.60 346.22 358.82 356.63 374.54 494.53 441.36 397.91 399.67 403.90
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 19,763 20,277 21,354 19,672 19,996 19,524 17,924 17,348 17,840 18,155
Invested Capital Turnover		 0.46 0.38 0.37 0.39 0.40 0.31 0.36 0.39 0.42 0.43
Increase / (Decrease) in Invested Capital		 13,482 514 1,076 -1,682 324 -473 -1,600 -577 492 315
Enterprise Value (EV)		 28,856 29,538 32,170 28,098 36,483 37,524 31,949 31,651 30,576 26,715
Market Capitalization		 18,981 18,930 22,553 19,697 28,875 30,194 25,252 26,324 25,216 21,028
Book Value per Share		 $48.52 $48.27 $57.96 $55.26 $60.23 $58.83 $60.60 $57.28 $59.72 $62.63
Tangible Book Value per Share		 ($43.15) ($48.73) ($35.99) ($29.45) ($21.73) ($19.89) ($8.58) ($7.74) ($5.72) ($5.43)
Total Capital		 21,387 20,911 21,878 20,215 20,614 20,326 19,735 17,724 18,256 18,681
Total Debt		 11,497 11,241 10,143 8,939 8,221 8,127 7,069 5,697 5,768 6,205
Total Long-Term Debt		 11,497 10,666 8,918 8,414 6,721 7,627 5,464 5,152 4,868 5,342
Net Debt		 9,874 10,607 9,618 8,396 7,604 7,324 6,691 5,321 5,352 5,679
Capital Expenditures (CapEx)		 98 185 156 163 207 112 144 188 291 204
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 2,612 2,224 2,196 1,988 2,165 2,224 2,644 2,238 2,236 2,558
Debt-free Net Working Capital (DFNWC)		 4,236 2,858 2,720 2,531 2,782 3,026 3,022 2,613 2,652 3,084
Net Working Capital (NWC)		 4,236 2,282 1,495 2,006 1,282 2,526 1,417 2,069 1,752 2,221
Net Nonoperating Expense (NNE)		 300 321 1,306 403 289 196 366 271 203 219
Net Nonoperating Obligations (NNO)		 9,874 10,607 9,618 8,396 7,604 7,324 5,258 5,321 5,352 5,679
Total Depreciation and Amortization (D&A)		 712 1,039 1,063 1,041 1,006 898 938 926 952 996
Debt-free, Cash-free Net Working Capital to Revenue		 43.55% 29.20% 28.14% 25.06% 27.12% 36.30% 38.73% 32.24% 30.24% 33.31%
Debt-free Net Working Capital to Revenue		 70.62% 37.53% 34.86% 31.91% 34.86% 49.39% 44.27% 37.66% 35.87% 40.16%
Net Working Capital to Revenue		 70.62% 29.97% 19.16% 25.29% 16.07% 41.23% 20.76% 29.81% 23.70% 28.92%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.78 $1.53 $8.98 ($1.86) $5.52 ($0.67) $1.93 $1.10 $4.91 $4.45
Adjusted Weighted Average Basic Shares Outstanding		 187.40M 200M 201.90M 203.50M 205.10M 207M 208.60M 209.60M 208.70M 203.10M
Adjusted Diluted Earnings per Share		 $0.77 $1.51 $8.90 ($1.86) $5.47 ($0.67) $1.91 $1.10 $4.88 $4.43
Adjusted Weighted Average Diluted Shares Outstanding		 189.80M 202.40M 203.70M 203.50M 206.70M 207M 210.40M 210.30M 209.70M 203.90M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 198.83M 201.10M 203.15M 204.43M 206.40M 207.86M 209.18M 208.98M 205.08M 199.06M
Normalized Net Operating Profit after Tax (NOPAT)		 1,247 1,034 804 733 880 493 895 860 1,373 1,314
Normalized NOPAT Margin		 20.79% 13.58% 10.30% 9.24% 11.03% 8.05% 13.11% 12.40% 18.57% 17.11%
Pre Tax Income Margin		 2.55% 5.25% 5.95% -3.42% 11.35% -1.72% 7.31% 5.81% 14.43% 13.50%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 1.50 2.13 2.43 0.06 4.99 0.50 2.34 3.45 6.30 5.76
NOPAT to Interest Expense		 1.56 1.76 9.59 0.08 6.26 0.27 2.06 3.05 6.10 5.15
EBIT Less CapEx to Interest Expense		 1.16 1.61 1.95 -0.50 4.08 -0.02 1.95 2.31 4.86 4.82
NOPAT Less CapEx to Interest Expense		 1.21 1.24 9.11 -0.48 5.35 -0.25 1.67 1.91 4.65 4.22
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 107.46% 61.85% 10.68% -51.46% 17.38% -144.47% 85.93% 86.95% 19.62% 21.69%
Augmented Payout Ratio		 210.05% 198.26% 10.68% -51.46% 17.38% -144.47% 85.93% 141.57% 87.22% 117.73%

Quarterly Metrics and Ratios for Zimmer Biomet

This table displays calculated financial ratios and metrics derived from Zimmer Biomet's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -0.93% 2.70% 10.09% 4.93% 5.02% 6.30% 3.18% 3.87% 4.03% 4.29%
EBITDA Growth		 -5.25% -45.95% 50.70% 20.15% 13.36% 193.33% -11.01% 5.41% 4.67% 6.72%
EBIT Growth		 -9.62% -124.77% 135.42% 37.81% 22.97% 1,139.13% -20.66% 7.58% 5.25% 4.87%
NOPAT Growth		 29.62% -121.15% 85.05% 15.27% -26.18% 2,737.67% -19.56% 13.07% 52.74% -38.15%
Net Income Growth		 33.24% -55.60% 1,516.67% 36.37% -16.13% 420.51% -25.77% 15.84% 53.10% -42.92%
EPS Growth		 33.33% -58.97% 1,485.71% 36.99% -16.30% 422.58% -24.32% 18.00% 59.74% -41.00%
Operating Cash Flow Growth		 6.27% -27.67% -2.53% 0.69% -25.11% 140.95% -25.90% 6.18% 17.21% -13.95%
Free Cash Flow Firm Growth		 1,857.91% -67.12% -70.64% -86.81% -104.20% -94.59% -133.36% -146.47% -182.32% -73.51%
Invested Capital Growth		 -9.73% -3.22% -1.51% 0.03% 1.65% 2.84% 2.23% 2.23% 3.14% 1.77%
Revenue Q/Q Growth		 -6.29% 9.30% 0.32% 2.11% -6.20% 10.63% -2.62% 2.79% -6.07% 10.91%
EBITDA Q/Q Growth		 -4.18% -56.50% 188.74% -0.16% -9.60% 12.55% -12.40% 18.26% -10.23% 14.75%
EBIT Q/Q Growth		 -7.72% -114.64% 1,140.37% -1.97% -17.66% 23.74% -20.56% 32.92% -19.45% 23.30%
NOPAT Q/Q Growth		 23.70% -107.39% 1,440.54% -5.88% -20.78% 163.90% -59.12% 32.30% 7.02% 6.86%
Net Income Q/Q Growth		 26.22% -167.37% 278.12% -9.97% -22.38% 157.47% -58.75% 40.51% 2.59% -4.01%
EPS Q/Q Growth		 26.03% -167.39% 279.03% -9.91% -23.00% 159.74% -58.00% 40.48% 4.24% -4.07%
Operating Cash Flow Q/Q Growth		 30.48% -45.83% 26.00% 13.06% -2.96% 74.29% -61.25% 62.02% 7.12% 27.95%
Free Cash Flow Firm Q/Q Growth		 16.15% -74.07% -3.94% -54.40% -136.95% 133.43% -692.21% 36.49% -124.50% 103.14%
Invested Capital Q/Q Growth		 -1.93% -0.41% 1.55% 0.86% -0.34% 0.75% 0.95% 0.86% 0.55% -0.60%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 70.76% 71.49% 72.65% 71.89% 70.43% 72.22% 72.88% 71.49% 70.47% 71.00%
EBITDA Margin		 27.03% 10.76% 30.96% 30.27% 29.17% 29.68% 26.70% 30.72% 29.36% 30.37%
Operating Margin		 14.69% -1.55% 17.88% 17.63% 15.20% 18.26% 14.07% 18.09% 15.32% 19.23%
EBIT Margin		 13.17% -1.76% 18.30% 17.57% 15.42% 17.25% 14.07% 18.19% 15.60% 17.34%
Profit (Net Income) Margin		 11.62% -7.16% 12.71% 11.21% 9.28% 21.59% 9.15% 12.50% 13.66% 11.82%
Tax Burden Percent		 109.23% 174.73% 81.17% 75.72% 74.22% 147.24% 80.33% 80.34% 108.16% 82.73%
Interest Burden Percent		 80.76% 232.30% 85.61% 84.29% 81.07% 85.03% 80.93% 85.54% 80.92% 82.36%
Effective Tax Rate		 -9.35% 0.00% 18.86% 24.17% 25.73% -47.52% 19.67% 19.56% -8.21% 16.92%
Return on Invested Capital (ROIC)		 6.03% -0.43% 5.81% 5.41% 4.68% 11.32% 4.73% 6.09% 7.00% 6.82%
ROIC Less NNEP Spread (ROIC-NNEP)		 4.77% -2.52% 5.23% 4.68% 4.00% 9.38% 3.98% 5.36% 6.04% 5.29%
Return on Net Nonoperating Assets (RNNOA)		 2.24% -1.08% 2.45% 2.11% 1.67% 4.08% 1.75% 2.30% 2.68% 2.34%
Return on Equity (ROE)		 8.27% -1.51% 8.26% 7.52% 6.35% 15.40% 6.48% 8.40% 9.69% 9.15%
Cash Return on Invested Capital (CROIC)		 14.58% 6.12% 5.07% 3.71% 1.78% 4.18% 4.42% 4.53% 4.21% 4.49%
Operating Return on Assets (OROA)		 4.00% -0.55% 6.07% 5.91% 5.28% 5.99% 4.91% 6.39% 5.52% 6.21%
Return on Assets (ROA)		 3.53% -2.23% 4.22% 3.77% 3.17% 7.50% 3.19% 4.39% 4.83% 4.23%
Return on Common Equity (ROCE)		 8.27% -1.51% 8.25% 7.52% 6.35% 15.39% 6.47% 8.39% 9.68% 9.15%
Return on Equity Simple (ROE_SIMPLE)		 2.27% 0.00% 3.70% 4.09% 3.79% 0.00% 7.65% 7.83% 8.76% 0.00%
Net Operating Profit after Tax (NOPAT)		 268 -20 266 250 198 523 214 283 302 323
NOPAT Margin		 16.06% -1.09% 14.50% 13.37% 11.29% 26.93% 11.31% 14.55% 16.58% 15.97%
Net Nonoperating Expense Percent (NNEP)		 1.26% 2.10% 0.58% 0.73% 0.68% 1.94% 0.75% 0.74% 0.96% 1.52%
Return On Investment Capital (ROIC_SIMPLE)		 1.49% -0.11% 1.48% 1.38% 1.10% 2.86% 1.16% 1.52% 1.61% 1.73%
Cost of Revenue to Revenue		 29.24% 28.51% 27.35% 28.11% 29.57% 27.78% 27.12% 28.51% 29.53% 29.00%
SG&A Expenses to Revenue		 39.22% 39.84% 39.10% 38.82% 38.49% 37.23% 38.97% 37.96% 38.90% 36.91%
R&D to Revenue		 6.09% 5.92% 6.03% 6.32% 6.67% 5.84% 5.71% 5.63% 6.12% 5.36%
Operating Expenses to Revenue		 56.07% 73.04% 54.77% 54.26% 55.22% 53.97% 58.81% 53.41% 55.15% 51.77%
Earnings before Interest and Taxes (EBIT)		 220 -32 335 328 270 335 266 353 285 351
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 451 196 567 566 512 576 504 597 536 615
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.76 2.19 2.19 2.42 1.85 2.02 2.17 1.74 1.77 1.69
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 3.13 3.79 3.74 4.17 3.19 3.41 3.68 2.95 2.89 2.74
Price to Earnings (P/E)		 77.57 114.25 59.31 59.41 49.01 24.65 28.46 22.32 20.27 23.31
Dividend Yield		 0.94% 0.77% 0.75% 0.67% 0.86% 0.80% 0.73% 0.89% 0.89% 0.91%
Earnings Yield		 1.29% 0.88% 1.69% 1.68% 2.04% 4.06% 3.51% 4.48% 4.93% 4.29%
Enterprise Value to Invested Capital (EV/IC)		 1.53 1.82 1.82 1.99 1.60 1.71 1.82 1.52 1.52 1.47
Enterprise Value to Revenue (EV/Rev)		 3.88 4.56 4.51 4.92 3.90 4.14 4.40 3.67 3.66 3.48
Enterprise Value to EBITDA (EV/EBITDA)		 16.08 21.18 19.03 19.87 15.43 13.77 15.21 12.64 12.58 11.87
Enterprise Value to EBIT (EV/EBIT)		 36.57 55.69 42.16 41.57 31.50 24.11 27.36 22.59 22.47 21.29
Enterprise Value to NOPAT (EV/NOPAT)		 33.47 62.99 50.81 53.26 47.27 24.92 27.82 22.84 21.16 23.80
Enterprise Value to Operating Cash Flow (EV/OCF)		 18.43 23.34 23.80 26.20 22.95 19.33 21.84 18.15 17.59 17.82
Enterprise Value to Free Cash Flow (EV/FCFF)		 9.98 29.33 35.62 53.75 90.81 41.61 41.68 33.94 36.71 33.08
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.47 0.47 0.48 0.46 0.44 0.46 0.46 0.46 0.52 0.50
Long-Term Debt to Equity		 0.41 0.43 0.43 0.42 0.41 0.39 0.38 0.31 0.38 0.43
Financial Leverage		 0.47 0.43 0.47 0.45 0.42 0.44 0.44 0.43 0.44 0.44
Leverage Ratio		 1.82 1.80 1.77 1.74 1.72 1.74 1.72 1.70 1.72 1.72
Compound Leverage Factor		 1.47 4.19 1.52 1.47 1.39 1.48 1.40 1.46 1.40 1.41
Debt to Total Capital		 31.81% 32.14% 32.26% 31.56% 30.46% 31.59% 31.50% 31.40% 34.25% 33.21%
Short-Term Debt to Total Capital		 3.67% 3.07% 3.26% 2.87% 1.97% 4.93% 5.27% 10.11% 9.10% 4.62%
Long-Term Debt to Total Capital		 28.14% 29.07% 29.00% 28.69% 28.48% 26.66% 26.23% 21.29% 25.16% 28.59%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.05% 0.05% 0.04%
Common Equity to Total Capital		 68.16% 67.82% 67.70% 68.40% 69.50% 68.36% 68.46% 68.56% 65.70% 66.74%
Debt to EBITDA		 3.44 3.81 3.44 3.21 2.98 2.60 2.69 2.67 2.92 2.76
Net Debt to EBITDA		 3.11 3.56 3.24 3.03 2.82 2.41 2.50 2.47 2.66 2.52
Long-Term Debt to EBITDA		 3.04 3.45 3.09 2.91 2.79 2.19 2.24 1.81 2.14 2.37
Debt to NOPAT		 7.16 11.34 9.17 8.59 9.12 4.70 4.92 4.82 4.91 5.53
Net Debt to NOPAT		 6.48 10.59 8.65 8.11 8.64 4.36 4.58 4.47 4.47 5.06
Long-Term Debt to NOPAT		 6.33 10.25 8.24 7.81 8.53 3.97 4.09 3.27 3.60 4.76
Altman Z-Score		 2.55 2.82 2.90 3.18 2.78 2.85 3.03 2.68 2.58 2.68
Noncontrolling Interest Sharing Ratio		 0.05% 0.05% 0.05% 0.05% 0.05% 0.06% 0.06% 0.06% 0.06% 0.06%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 1.98 1.88 1.89 1.96 2.11 1.61 1.66 1.29 1.36 1.91
Quick Ratio		 0.79 0.75 0.73 0.76 0.79 0.65 0.66 0.51 0.57 0.82
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 2,147 557 535 244 -90 30 -178 -113 -254 7.98
Operating Cash Flow to CapEx		 955.08% 385.17% 658.89% 357.55% 400.47% 936.94% 413.79% 700.95% 889.21% 983.11%
Free Cash Flow to Firm to Interest Expense		 50.75 13.07 11.09 4.73 -1.76 0.60 -3.52 -2.22 -4.68 0.13
Operating Cash Flow to Interest Expense		 10.66 5.73 6.38 6.74 6.61 11.70 4.50 7.23 7.29 8.18
Operating Cash Flow Less CapEx to Interest Expense		 9.54 4.24 5.41 4.86 4.96 10.45 3.41 6.20 6.47 7.35
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.30 0.31 0.33 0.34 0.34 0.35 0.35 0.35 0.35 0.36
Accounts Receivable Turnover		 5.16 5.26 5.39 5.43 5.56 5.24 5.27 5.40 5.38 5.25
Inventory Turnover		 0.88 0.94 0.92 0.93 0.93 0.92 0.91 0.91 0.91 0.95
Fixed Asset Turnover		 3.62 3.74 3.81 3.82 3.80 3.76 3.73 3.69 3.67 3.74
Accounts Payable Turnover		 6.15 6.11 5.62 6.15 6.32 5.45 5.46 6.10 6.68 7.24
Days Sales Outstanding (DSO)		 70.71 69.45 67.66 67.20 65.67 69.70 69.24 67.55 67.81 69.47
Days Inventory Outstanding (DIO)		 416.51 388.15 395.06 394.50 393.41 396.95 403.23 399.28 399.50 384.83
Days Payable Outstanding (DPO)		 59.30 59.70 64.96 59.35 57.76 66.97 66.84 59.85 54.67 50.41
Cash Conversion Cycle (CCC)		 427.92 397.91 397.76 402.35 401.32 399.67 405.62 406.98 412.64 403.90
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 17,420 17,348 17,617 17,768 17,708 17,840 18,009 18,164 18,265 18,155
Invested Capital Turnover		 0.38 0.39 0.40 0.41 0.41 0.42 0.42 0.42 0.42 0.43
Increase / (Decrease) in Invested Capital		 -1,878 -577 -269 6.10 288 492 392 396 557 315
Enterprise Value (EV)		 26,716 31,651 32,081 35,380 28,401 30,576 32,809 27,651 27,825 26,715
Market Capitalization		 21,541 26,324 26,614 29,984 23,204 25,216 27,397 22,228 21,935 21,028
Book Value per Share		 $58.36 $57.28 $58.14 $59.32 $59.87 $59.72 $61.39 $61.93 $60.76 $62.63
Tangible Book Value per Share		 ($8.06) ($7.74) ($7.92) ($6.71) ($5.22) ($5.72) ($4.52) ($3.84) ($5.91) ($5.43)
Total Capital		 17,965 17,724 17,947 18,088 18,000 18,256 18,402 18,584 18,834 18,681
Total Debt		 5,714 5,697 5,790 5,709 5,482 5,768 5,796 5,835 6,451 6,205
Total Long-Term Debt		 5,055 5,152 5,205 5,189 5,127 4,868 4,826 3,957 4,738 5,342
Net Debt		 5,169 5,321 5,460 5,390 5,190 5,352 5,403 5,415 5,882 5,679
Capital Expenditures (CapEx)		 47 63 47 97 84 63 55 53 45 52
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 2,352 2,238 2,331 2,354 2,363 2,236 2,412 2,489 2,437 2,558
Debt-free Net Working Capital (DFNWC)		 2,898 2,613 2,661 2,674 2,656 2,652 2,805 2,909 3,006 3,084
Net Working Capital (NWC)		 2,239 2,069 2,076 2,154 2,301 1,752 1,835 1,031 1,293 2,221
Net Nonoperating Expense (NNE)		 74 111 33 40 35 104 41 40 53 84
Net Nonoperating Obligations (NNO)		 5,169 5,321 5,460 5,390 5,190 5,352 5,403 5,415 5,882 5,679
Total Depreciation and Amortization (D&A)		 231 229 232 238 241 241 239 243 251 264
Debt-free, Cash-free Net Working Capital to Revenue		 34.13% 32.24% 32.79% 32.72% 32.47% 30.24% 32.36% 33.08% 32.08% 33.31%
Debt-free Net Working Capital to Revenue		 42.05% 37.66% 37.44% 37.16% 36.48% 35.87% 37.63% 38.66% 39.57% 40.16%
Net Working Capital to Revenue		 32.48% 29.81% 29.21% 29.94% 31.60% 23.70% 24.62% 13.70% 17.02% 28.92%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.92 ($0.62) $1.11 $1.00 $0.78 $2.02 $0.84 $1.18 $1.23 $1.20
Adjusted Weighted Average Basic Shares Outstanding		 209.80M 209.60M 209.40M 208.60M 208.90M 208.70M 205.20M 205.70M 202.30M 203.10M
Adjusted Diluted Earnings per Share		 $0.92 ($0.62) $1.11 $1.00 $0.77 $2.00 $0.84 $1.18 $1.23 $1.18
Adjusted Weighted Average Diluted Shares Outstanding		 210.30M 210.30M 210.40M 209.90M 210M 209.70M 206.20M 206.40M 203M 203.90M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 209.85M 208.98M 208.57M 208.96M 208.98M 205.08M 205.73M 203.65M 199.07M 199.06M
Normalized Net Operating Profit after Tax (NOPAT)		 192 32 299 268 216 291 314 316 218 341
Normalized NOPAT Margin		 11.47% 1.75% 16.36% 14.36% 12.32% 15.00% 16.60% 16.27% 11.96% 16.83%
Pre Tax Income Margin		 10.64% -4.10% 15.66% 14.81% 12.50% 14.66% 11.39% 15.56% 12.62% 14.28%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 5.20 -0.76 6.95 6.36 5.29 6.65 5.24 6.91 5.24 5.67
NOPAT to Interest Expense		 6.34 -0.47 5.51 4.84 3.87 10.39 4.21 5.53 5.57 5.22
EBIT Less CapEx to Interest Expense		 4.08 -2.24 5.98 4.48 3.64 5.40 4.16 5.88 4.42 4.84
NOPAT Less CapEx to Interest Expense		 5.23 -1.95 4.54 2.96 2.23 9.14 3.13 4.50 4.75 4.39
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 88.46% 86.95% 44.75% 40.60% 43.23% 19.62% 20.90% 20.35% 18.73% 21.69%
Augmented Payout Ratio		 88.46% 141.57% 132.35% 121.34% 129.30% 87.22% 76.73% 81.50% 130.04% 117.73%

Frequently Asked Questions About Zimmer Biomet's Financials

When does Zimmer Biomet's financial year end?

According to the most recent income statement we have on file, Zimmer Biomet's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Zimmer Biomet's net income changed over the last 9 years?

Zimmer Biomet's net income appears to be on an upward trend, with a most recent value of $903.80 million in 2024, rising from $146.20 million in 2015. The previous period was $1.02 billion in 2023.

What is Zimmer Biomet's operating income?
Zimmer Biomet's total operating income in 2024 was $1.29 billion, based on the following breakdown:
  • Total Gross Profit: $5.49 billion
  • Total Operating Expenses: $4.20 billion
How has Zimmer Biomet revenue changed over the last 9 years?

Over the last 9 years, Zimmer Biomet's total revenue changed from $6.00 billion in 2015 to $7.68 billion in 2024, a change of 28.0%.

How much debt does Zimmer Biomet have?

Zimmer Biomet's total liabilities were at $8.89 billion at the end of 2024, a 1.3% decrease from 2023, and a 48.5% decrease since 2015.

How much cash does Zimmer Biomet have?

In the past 9 years, Zimmer Biomet's cash and equivalents has ranged from $375.70 million in 2022 to $1.46 billion in 2015, and is currently $525.50 million as of their latest financial filing in 2024.

How has Zimmer Biomet's book value per share changed over the last 9 years?

Over the last 9 years, Zimmer Biomet's book value per share changed from 48.52 in 2015 to 62.63 in 2024, a change of 29.1%.

Remove Ads

Related Companies

This page (NYSE:ZBH) was last updated on 4/14/2025 by MarketBeat.com Staff
From Our Partners
Elon Set to Shock the World by May 1st ?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...
Brownstone Research | Sponsored
America’s Retirement Accounts Are at Risk—Here’s Why
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
Tariffs. Volatility. Fear. Here’s the Plan.
Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...
Investors Alley | Sponsored
The Last Time This Happened, Americans Lost Billions
Wall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...
Banyan Hill Publishing | Sponsored
Catastrophic
The losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.
InvestorPlace | Sponsored
Trump’s betrayal exposed
Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...
Porter & Company | Sponsored
Trump 2028 could be a “bonanza” for investors
As you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...
Paradigm Press | Sponsored